AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29669086 — intervention group
Group type: EXPERIMENTAL
Intervention: WL group (wait-list control)
Number of subjects: 60
Study 26589765 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-Supported PTSD Coach (4 sessions of 20 minutes each)
Number of subjects: 20
Study 26589765 — intervention group
Group type: COMPARATOR
Intervention: Self-Managed PTSD Coach (1 session of 10 minutes)
Number of subjects: 20
Study 26589765 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-Supported PTSD Coach
Number of subjects: 20
Study 25218505 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrocnemii forces during single-leg jump landing
Number of subjects: 6
Study 25218505 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps forces during single-leg jump landing
Number of subjects: 6
Study 25218505 — intervention group
Group type: COMPARATOR
Intervention: Hamstrings forces during single-leg jump landing
Number of subjects: 6
Study 23322574 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 12
Study 23322574 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 19837556 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage clamping for no less than 4 hours
Number of subjects: 603
Study 19837556 — intervention group
Group type: COMPARATOR
Intervention: Immediate release of the drain after elective TKA
Number of subjects: 603
Study 18639581 — intervention group
Group type: EXPERIMENTAL
Intervention: MSB‐N (Experimental I)
Number of subjects: 476
Study 18639581 — intervention group
Group type: EXPERIMENTAL
Intervention: MSB‐N plus Booster (Experimental II)
Number of subjects: 476
Study 18639581 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control group (C)
Number of subjects: 476
Study 16973496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa polyphenols supplementation
Number of subjects: 16
Study 16973496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16973496 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (1-h cycling at 70% VO2max)
Number of subjects: 16
Study 15469609 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural graded activity programme
Number of subjects: 0
Study 15469609 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy treatment
Number of subjects: 0
Study 10661483 — intervention group
Group type: COMPARATOR
Intervention: Standard blood flow and saline flush (125 ml/min and 100 ml once hourly)
Number of subjects: 34
Study 10661483 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented blood flow and saline flush (200‐250 ml/min and 100 ml twice hourly)
Number of subjects: 34
Study 10661483 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell and platelet transfusion during CRRT
Number of subjects: 34
Study 10661483 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic heparin infusion
Number of subjects: 34
Study 9310283 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 envelope vaccines (recombinant and synthetic); specific adjuvants include alum plus deoxycholate, MTP-PE, QS21
Number of subjects: 1398
Study 9310283 — intervention group
Group type: COMPARATOR
Intervention: Placebo (adjuvant alone or vector with no gene insert/non-HIV gene insert)
Number of subjects: 1398
Study 8312687 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (3 x 25 mg daily for 7 days)
Number of subjects: 28
Study 8312687 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 28
Study 3531308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 382
Study 3531308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine treatment in second 4-week period for 124 unhealed patients
Number of subjects: 382
Study 3531308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 31562600 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical margin excision of not more than 2 cm
Number of subjects: 0
Study 31562600 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up data from RCTs
Number of subjects: 0
Study 31562600 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary trial enrolling patients
Number of subjects: 0
Study 31195357 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab
Number of subjects: 0
Study 31195357 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 25774646 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention (9 postcards over 12 months plus usual treatment)
Number of subjects: 2300
Study 25774646 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 2300
Study 25850425 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2217
Study 25850425 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2217
Study 23421734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 62
Study 23421734 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 62
Study 21120518 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 3 mg kg(‐1)
Number of subjects: 11
Study 21120518 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 21120518 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 11
Study 21120518 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (CAF) and Placebo (PLA)
Number of subjects: 11
Study 19248105 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection (2.5 ml)
Number of subjects: 85
Study 19248105 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (2.5 ml)
Number of subjects: 85
Study 17958934 — intervention group
Group type: EXPERIMENTAL
Intervention: DICOM transmission of stereoscopic images
Number of subjects: 15
Study 15000637 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated potassium nitrate/dimethyl isosorbide in aqueous hydroxyethyl cellulose gel
Number of subjects: 0
Study 11723147 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate meal (25 g)
Number of subjects: 12
Study 11723147 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-carbohydrate meal (65 g)
Number of subjects: 12
Study 11723147 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (125 g)
Number of subjects: 12
Study 9340918 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis
Number of subjects: 0
Study 9340918 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate revascularisation
Number of subjects: 0
Study 9340918 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers and platelet aggregation inhibitors
Number of subjects: 0
Study 9340918 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitors
Number of subjects: 0
Study 8033658 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) group, 10% Intralipid and 5% Nutrisol‐S for 10‐20 days
Number of subjects: 25
Study 8033658 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 3565242 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided dosing (Bayesian forecasting technique)
Number of subjects: 63
Study 3565242 — intervention group
Group type: COMPARATOR
Intervention: Control (unaided physician dosing)
Number of subjects: 63
Study 3565242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine concentrations greater than 2 mg/L
Number of subjects: 63
Study 31852769 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g FMT
Number of subjects: 165
Study 31852769 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g FMT
Number of subjects: 165
Study 31852769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (own faeces)
Number of subjects: 165
Study 30871355 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel early loading (EL) before PCI
Number of subjects: 5438
Study 30871355 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel late loading (LL) after PCI
Number of subjects: 5438
Study 30871355 — intervention group
Group type: COMPARATOR
Intervention: Cangrelor
Number of subjects: 5438
Study 30871355 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel early loading (EL)
Number of subjects: 5438
Study 30871355 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel late loading (LL)
Number of subjects: 5438
Study 28017518 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-management and muscle relaxation program administered once a week for 1 hour over 3 months
Number of subjects: 74
Study 28017518 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 74
Study 25987072 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium injected 20 min before anesthesia induction (Trial Group I)
Number of subjects: 57
Study 25987072 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium injected 20 min before anesthesia induction and again 12 h after surgery (Trial Group II)
Number of subjects: 57
Study 25987072 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection before anesthesia induction (Control Group)
Number of subjects: 57
Study 22653766 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine beclomethasone dipropionate and formoterol in a combination inhaler
Number of subjects: 0
Study 22653766 — intervention group
Group type: COMPARATOR
Intervention: Extrafine formoterol
Number of subjects: 0
Study 22653766 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional physician diagnosis of exacerbations
Number of subjects: 0
Study 22653766 — intervention group
Group type: EXPERIMENTAL
Intervention: EXACT (Exacerbations of Chronic Pulmonary Disease Tool)
Number of subjects: 0
Study 22718671 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Valeriana Officinalis L. (765 mg/day)
Number of subjects: 31
Study 22718671 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 mg/day)
Number of subjects: 31
Study 19384840 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (initial dose 5 mg, increased to 10 mg, 20 mg, and 40 mg over 16 weeks)
Number of subjects: 25
Study 23118648 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rHuEPO 300 units/kg/day
Number of subjects: 27
Study 23118648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 14623807 — intervention group
Group type: EXPERIMENTAL
Intervention: Water ingestion (16 oz / 473 mL) 5 minutes before tilt-table testing
Number of subjects: 22
Study 11099602 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma CO and NO levels in asphyxiated term neonates with HIE
Number of subjects: 63
Study 11099602 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma CO and NO levels in neonates with HIE stage 3
Number of subjects: 63
Study 11099602 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma CO and NO levels in neonates with brain damage and adverse outcome
Number of subjects: 63
Study 11099602 — intervention group
Group type: COMPARATOR
Intervention: Healthy neonates (control group)
Number of subjects: 63
Study 8783054 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid water (AW) prepared by an electrolysis apparatus, pH 2.7, 30s washing 2X daily for 7 days
Number of subjects: 12
Study 8783054 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate (CHX) solution, 30s washing 2X daily for 7 days
Number of subjects: 12
Study 8783054 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution, 30s washing 2X daily for 7 days
Number of subjects: 12
Study 8783054 — intervention group
Group type: COMPARATOR
Intervention: No washing (control group), 30s washing 2X daily for 7 days
Number of subjects: 12
Study 1292967 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 1‐44 NH2 (30 to 300 micrograms/day, injected subcutaneously every evening for six months)
Number of subjects: 111
Study 6740489 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical rotation in different surgical settings
Number of subjects: 104
Study 6740489 — intervention group
Group type: EXPERIMENTAL
Intervention: Order of completion of PMPs
Number of subjects: 104
Study 30733197 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic hip surgery
Number of subjects: 222
Study 30733197 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy and activity modification
Number of subjects: 222
Study 29807228 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1200 mg
Number of subjects: 244
Study 29807228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 26922462 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (25, 40, 60, 80, or 100 mg daily)
Number of subjects: 1003
Study 26922462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1003
Study 24935221 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE Plus
Number of subjects: 1060
Study 24935221 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE
Number of subjects: 1060
Study 24935221 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1060
Study 23154439 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual Learning Program (SLP), 8 weeks, 50 minutes per week, including lectures, discussion, reflection, and spiritual practices.
Number of subjects: 0
Study 23154439 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual Learning Program (SLP)
Number of subjects: 0
Study 23154439 — intervention group
Group type: EXPERIMENTAL
Intervention: Final clinical practice scores from the experimental group
Number of subjects: 0
Study 20595119 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed intramedullary nailing
Number of subjects: 85
Study 20595119 — intervention group
Group type: COMPARATOR
Intervention: Locked compression plate
Number of subjects: 85
Study 20595119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 85
Study 18580552 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral electroconvulsive therapy (ECT) at 150% above the measured seizure threshold (ST)
Number of subjects: 80
Study 15967567 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg propiverine twice daily
Number of subjects: 202
Study 15967567 — intervention group
Group type: COMPARATOR
Intervention: 2 mg tolterodine twice daily
Number of subjects: 202
Study 12012145 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed and clinically relevant data on asthma drug prescribing patterns and a guideline statement
Number of subjects: 292
Study 12012145 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate data on asthma drug prescribing patterns and a guideline statement
Number of subjects: 292
Study 12012145 — intervention group
Group type: COMPARATOR
Intervention: Feedback on an unrelated subject
Number of subjects: 292
Study 10386467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 240 mg polyestradiol phosphate (PEP) every second week for the first 8 weeks, followed by a maintenance dose of 240 mg every month
Number of subjects: 17
Study 10386467 — intervention group
Group type: COMPARATOR
Intervention: Bilateral orchidectomy
Number of subjects: 17
Study 8698375 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole 150 mg
Number of subjects: 157
Study 8698375 — intervention group
Group type: COMPARATOR
Intervention: Topical clotrimazole applied twice daily for 7 days
Number of subjects: 157
Study 1519716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/codeine combination (400 mg ibuprofen/25.6 mg codeine phosphate)
Number of subjects: 30
Study 1519716 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol/codeine/caffeine combination (1 g paracetamol/16 mg codeine phosphate/60 mg caffeine)
Number of subjects: 30
Study 6503363 — intervention group
Group type: COMPARATOR
Intervention: Low energy (200 to 240 J)
Number of subjects: 100
Study 6503363 — intervention group
Group type: COMPARATOR
Intervention: Intermediate energy (300 to 320 J)
Number of subjects: 100
Study 6503363 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy (400 to 440 J)
Number of subjects: 100
Study 6503363 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 J (maximal energy dose available in most defibrillators)
Number of subjects: 100
Study 6503363 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 100
Study 30409040 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture at 12:00 (noon condition)
Number of subjects: 78
Study 30409040 — intervention group
Group type: COMPARATOR
Intervention: Lecture at 19:30 (evening condition)
Number of subjects: 78
Study 30409040 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter sleep durations and later bedtimes
Number of subjects: 78
Study 30409040 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer sleep durations and earlier bedtimes
Number of subjects: 78
Study 30409040 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-median fluid intelligence scores
Number of subjects: 78
Study 29605103 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0
Study 29605103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29798036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Budesonide combined with fexofenadine hydrochloride (Group B)
Number of subjects: 96
Study 29798036 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide combined with montelukast (Group C)
Number of subjects: 96
Study 29798036 — intervention group
Group type: COMPARATOR
Intervention: Nasal Budesonide (Group A)
Number of subjects: 96
Study 24947722 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater LVM regression (more than median percentage change in LVMi)
Number of subjects: 690
Study 24947722 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater LVM regression
Number of subjects: 690
Study 24947722 — intervention group
Group type: COMPARATOR
Intervention: Lesser LVM regression
Number of subjects: 690
Study 22205636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion with mastication (chewing gum)
Number of subjects: 14
Study 22205636 — intervention group
Group type: COMPARATOR
Intervention: Ingestion without mastication (no chewing gum)
Number of subjects: 14
Study 22205636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion with mastication
Number of subjects: 14
Study 19053970 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 81
Study 19053970 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 81
Study 19053970 — intervention group
Group type: EXPERIMENTAL
Intervention: Open sequential treatment protocol (augmentation with lithium, switch to a monoamine oxidase inhibitor or ECT)
Number of subjects: 81
Study 19053970 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation with lithium
Number of subjects: 81
Study 17988728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/day
Number of subjects: 9795
Study 15628051 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental, atracurium besilate and fentanyl (Group I; n=27)
Number of subjects: 55
Study 15628051 — intervention group
Group type: COMPARATOR
Intervention: Propofol, vecuronium bromide and fentanyl (Group II; n=28)
Number of subjects: 55
Study 15628051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 10891019 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologists
Number of subjects: 1242
Study 10891019 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Workers
Number of subjects: 1242
Study 10891019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 1242
Study 10891019 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatricians
Number of subjects: 1242
Study 10891019 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologists and Social Workers
Number of subjects: 1242
Study 10891019 — intervention group
Group type: EXPERIMENTAL
Intervention: All Disciplines
Number of subjects: 1242
Study 9313601 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 0
Study 9313601 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release diltiazem
Number of subjects: 0
Study 8362305 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (3 doses of 500 mg at 6 hour intervals)
Number of subjects: 55
Study 8362305 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine (divided doses of 1,250 mg or 1,500 mg based on weight)
Number of subjects: 55
Study 3569678 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8
Study 3569678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2721543 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 3.75 mg
Number of subjects: 6
Study 2721543 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 6
Study 2721543 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 6
Study 2721543 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (various doses)
Number of subjects: 6
Study 2721543 — intervention group
Group type: COMPARATOR
Intervention: Triazolam 0.25 mg
Number of subjects: 6
Study 31806653 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (EQW)
Number of subjects: 14752
Study 31806653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14752
Study 31184785 — intervention group
Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing (LBBaP)
Number of subjects: 44
Study 31184785 — intervention group
Group type: COMPARATOR
Intervention: Conventional right ventricular pacing (RVP)
Number of subjects: 44
Study 27688143 — intervention group
Group type: EXPERIMENTAL
Intervention: Karate training
Number of subjects: 55
Study 27688143 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 55
Study 27688143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 55
Study 25950233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap group
Number of subjects: 34
Study 25950233 — intervention group
Group type: COMPARATOR
Intervention: Wake group
Number of subjects: 34
Study 22989264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 67
Study 22989264 — intervention group
Group type: COMPARATOR
Intervention: Non-fluvastatin (Control)
Number of subjects: 67